BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aivazian K, Long GV, Sinclair EC, Kench JG, McKenzie CA. Histopathology of pembrolizumab-induced hepatitis: a case report. Pathology 2017;49:789-92. [PMID: 29079004 DOI: 10.1016/j.pathol.2017.07.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Nasser NJ, Gorenberg M, Agbarya A. First line Immunotherapy for Non-Small Cell Lung Cancer. Pharmaceuticals (Basel) 2020;13:E373. [PMID: 33171686 DOI: 10.3390/ph13110373] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
2 Gkiala A, Palioura S. Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies. Clin Ophthalmol 2020;14:3137-52. [PMID: 33116365 DOI: 10.2147/OPTH.S271569] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Karamchandani DM, Chetty R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective. J Clin Pathol. 2018;71:665-671. [PMID: 29703758 DOI: 10.1136/jclinpath-2018-205143] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 15.5] [Reference Citation Analysis]
4 Villa-Ruano N, Guerrero-González T, Gómez-Conde E, Perez-Santos M. Bispecific anti-PD-L1/PD-1 antibodies for advanced solid tumors: a patent evaluation of US2019010232. Expert Opin Ther Pat 2020;30:723-7. [PMID: 32787475 DOI: 10.1080/13543776.2020.1810238] [Reference Citation Analysis]
5 Thorsteinsdottir T, Løitegård T, Reims HM, Porojnicu AC. Fatal Cholestatic Liver Injury during Treatment with PD1 Immune Checkpoint Inhibitor for Malignant Melanoma: A Case Report. Case Rep Oncol 2020;13:659-63. [PMID: 32774252 DOI: 10.1159/000507695] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Tan Y, Ye Y, Chen L. Fatal immune-related hepatitis with intrahepatic cholestasis and pneumonia associated with camrelizumab: A case report and literature review. Open Med (Wars) 2021;16:553-7. [PMID: 33869777 DOI: 10.1515/med-2021-0267] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sawada K, Hayashi H, Nakajima S, Hasebe T, Fujiya M, Okumura T. Non‐alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor. Journal of Gastroenterology and Hepatology 2020;35:1042-8. [DOI: 10.1111/jgh.14889] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
8 Zen Y, Yeh MM. Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy. Semin Diagn Pathol. 2019;36:434-440. [PMID: 31358424 DOI: 10.1053/j.semdp.2019.07.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 8.7] [Reference Citation Analysis]
9 Shah N, Jacob J, Househ Z, Shiner E, Baird L, Soudy H. Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab. J Immunother Cancer 2019;7:247. [PMID: 31511075 DOI: 10.1186/s40425-019-0727-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
10 Kurokawa K, Hara M, Iwakami SI, Genda T, Iwakami N, Miyashita Y, Fujioka M, Sasaki S, Takahashi K. Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma. Intern Med 2019;58:3283-7. [PMID: 31735738 DOI: 10.2169/internalmedicine.2591-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Bajwa R, Cheema A, Khan T, Amirpour A, Paul A, Chaughtai S, Patel S, Patel T, Bramson J, Gupta V, Levitt M, Asif A, Hossain MA. Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study. J Clin Med Res. 2019;11:225-236. [PMID: 30937112 DOI: 10.14740/jocmr3750] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 22.3] [Reference Citation Analysis]
12 Zen Y, Chen YY, Jeng YM, Tsai HW, Yeh MM. Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes. Histopathology. 2019;. [PMID: 31550390 DOI: 10.1111/his.14000] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]